Search Results for keywords:"hearing denial"

The Food and Drug Administration (FDA) has decided to deny Yong Sheng Jiao's request for a hearing and issued a final debarment order. Jiao, who pleaded guilty to felony charges related to importing a misbranded drug into the U.S., is barred for five years from providing services connected to drug application processes. The FDA determined that the seriousness of Jiao's offense warranted this punishment, despite Jiao's claims of misunderstanding and attempts to challenge the penalty's severity. The decision reflects the FDA's commitment to maintaining the safety and integrity of the drug industry in the United States.

The Food and Drug Administration (FDA) has denied Yong Sheng Jiao's request for a hearing and has banned him from importing or offering to import any drugs into the United States for five years. This decision stems from Jiao's conviction for importing misbranded drugs, specifically dipyrone, by mislabeling them as sebacic acid. Jiao tried to argue that he was not responsible for the misbranding, claiming it was his supplier's fault, but the FDA maintained that his guilty plea in court provided enough basis for the ban. The FDA determined a five-year ban was appropriate after weighing the seriousness of his offense against the few mitigating actions he took.